Genetics and Gene Therapy in Hunter Disease

Area of Science:

• Genetics and rare diseases
• Lysosomal storage disorders
• Gene therapy applications

Background:

• Hunter syndrome (Mucopolysaccharidosis type II) is an X-linked lysosomal storage disease.
• Caused by iduronate-2-sulfatase deficiency, leading to glycosaminoglycan accumulation.
• Current therapies have limitations, particularly in achieving central nervous system therapeutic levels.

Purpose of the Study:

• To explore gene therapy as a potential therapeutic option for Mucopolysaccharidosis type II.
• To evaluate the efficacy of viral vector-mediated gene transfer for enzyme replacement.
• To assess both in vivo and ex vivo gene therapy approaches in preclinical and early clinical settings.

Main Methods:

• In vitro studies demonstrating viral vector-mediated IDS gene expression and enzyme activity.
• Preclinical studies using animal models of Mucopolysaccharidosis II.
• In vivo administration of recombinant vectors (systemic or CNS-directed) and ex vivo gene therapy with autologous hematopoietic stem cells.

Main Results:

• In vitro studies confirmed high levels of enzyme activity in transduced cells.
• Preclinical studies in animal models showed promising results for gene therapy vectors.
• A Phase I clinical trial for mild Hunter syndrome patients was approved.

Conclusions:

• Gene therapy is a viable therapeutic strategy for Mucopolysaccharidosis type II.
• Further clinical application is necessary to validate gene therapy as a definitive treatment option.
• Gene therapy holds potential for addressing the multisystemic and CNS challenges of Hunter syndrome.